Roche’s Polivy Wins US Approval In Untreated Lymphoma But Blockbuster Potential Uncertain
Closely-Watched ADC
Executive Summary
The firm’s antibody-drug conjugate plus Rituxan and R-CHP chemoimmunotherapy has won a US thumbs up for first-line diffuse large B-cell lymphoma but lingering concerns about magnitude of benefit could lead to limited uptake.